AZ D5180C00018 DESTINATION: A multicentre double blind randomized placebo controlled parallel group phase 3 safety extension study to evaluate safety & tolerability of Tezepelumab
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
July 12, 2019
End Date
October 31, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
July 12, 2019
End Date
October 31, 2023